Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 8 April 2019, 10:43 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Start Your Day With a Sparkling Pop!

Containing 75 Lemons Worth of Vitamin C and 50% Less Calories!

TOKYO, Apr 8, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims, in Japan on Tuesday, April 9.


Chocola BB Sparkling Kiwi & Lemon Flavor is a new carbonated beverage classified by the Japanese Consumer Affairs Agency as a Food with Nutrient Function Claims (Niacin), and is the newest product flavor of the Chocola BB Sparkling series which has been well received mainly by working women since the series? initial launch in 2011. The drink contains five ingredients that help bring out women?s beauty from within, including 1500 mg of vitamin C which is equivalent to 75 lemons, in addition to vitamin B1, B6, iron, as well as niacin to help maintain the health of skin and mucosal membranes. Compared to the original Chocola BB Sparkling Grapefruit & Peach Flavor, calories have been reduced by 50% (24kcal).

By adding the new Chocola BB Sparkling Kiwi & Lemon Flavor with its fresh taste to the Chocola BB Sparkling lineup, consumers will be able to enjoy a choice between two flavors to match their personal needs for refreshment.

Eisai continues to provide the Chocola BB family of products to respond to the diverse needs of women and support a greater number of people to achieve health and beauty in their everyday lives.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 26, 2025 18:42 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 17, 2025 21:08 HKT/SGT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Oct 30, 2025 13:43 HKT/SGT
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 28, 2025 23:30 HKT/SGT
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Oct 27, 2025 13:23 HKT/SGT
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
Oct 14, 2025 16:54 HKT/SGT
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 8, 2025 11:03 HKT/SGT
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 3, 2025 17:01 HKT/SGT
Eisai Highlights Breadth of Oncology Research at ESMO 2025
Sept 29, 2025 09:33 HKT/SGT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
Sept 24, 2025 18:04 HKT/SGT
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: